Organon & Co. Short-Term Debt
Organon & Co. (OGN) had Short-Term Debt of $74.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current
us-gaap:DebtCurrent · last filed 2026-07-31
- 2026-06-30: Debt, Current $74.00M.
- 2026-03-31: Debt, Current $16.00M.
- 2025-12-31: Debt, Current $16.00M.
- 2025-09-30: Debt, Current $45.00M.
| Period end | Debt, Current |
|---|---|
| 2026-06-30 | $74.00M 10-Q · filed 2026-07-31 |
| 2026-03-31 | $16.00M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $16.00M 10-Q · filed 2026-07-31 |
| 2025-09-30 | $45.00M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $115.00M 10-Q · filed 2025-08-06 |
| 2024-12-31 | $20.00M 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |